AR058705A1 - Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1) - Google Patents
Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1)Info
- Publication number
- AR058705A1 AR058705A1 ARP060105673A ARP060105673A AR058705A1 AR 058705 A1 AR058705 A1 AR 058705A1 AR P060105673 A ARP060105673 A AR P060105673A AR P060105673 A ARP060105673 A AR P060105673A AR 058705 A1 AR058705 A1 AR 058705A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- alkoxy
- halo
- vaniloid
- bencimidazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Procesos para su preparacion y a nuevos intermediarios utilizados en la preparacion de los mismos, a composiciones farmacéuticas que contienen dichos compuestos y al uso de dichos compuestos para dolor agudo, neuropático, inflamatorio, enfermedades respiratorias, asma, artrosis, psoriasis. Reivindicacion 1: Un compuesto que tiene la formula (1): donde: R1 está seleccionado de nitro, ciano, halo y acetilo; R2 está seleccionado de fenilo, heteroarilo, fenilmetilo y feniloximetilo; donde R2 está opcionalmente sustituido con uno o más sustituyentes Q seleccionados de alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, halo, haloalcoxi C1-6, cicloalcoxi C3-7, cicloalquilo C3-7, alquinilo C1-6, cicloalquilalcoxi C3-7, heterocicloalquiloxi C3-7, y alcoxi C1-3 alcoxi C1-6, donde dicho(s) sustituyente(s) Q está(n) unido(s) al o a los anillos(s) aromáticos(s) y/o heteroaromáticos(s) de R2; R3 es H o F; R4 es metilo, metoxicarbonilo o etilo; o R2 y R4 pueden formar conjuntamente un sistema de anillo monocíclico o bicíclico; y sales, solvatos o sales solvatadas del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75360405P | 2005-12-23 | 2005-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR058705A1 true AR058705A1 (es) | 2008-02-20 |
Family
ID=38189102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060105673A AR058705A1 (es) | 2005-12-23 | 2006-12-20 | Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1) |
Country Status (22)
Country | Link |
---|---|
US (2) | US7618993B2 (es) |
EP (1) | EP1966156B1 (es) |
JP (1) | JP2009521431A (es) |
KR (1) | KR20080080212A (es) |
CN (1) | CN101389610B (es) |
AR (1) | AR058705A1 (es) |
AT (1) | ATE538101T1 (es) |
AU (1) | AU2006327320B2 (es) |
BR (1) | BRPI0620410A2 (es) |
CA (1) | CA2634804A1 (es) |
EC (1) | ECSP088584A (es) |
ES (1) | ES2377661T3 (es) |
HK (1) | HK1121755A1 (es) |
IL (1) | IL191753A0 (es) |
NO (1) | NO20083246L (es) |
NZ (1) | NZ569923A (es) |
RU (1) | RU2427573C2 (es) |
TW (1) | TW200736227A (es) |
UA (1) | UA96277C2 (es) |
UY (1) | UY30048A1 (es) |
WO (1) | WO2007073303A2 (es) |
ZA (1) | ZA200805162B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0301446D0 (sv) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
AR058705A1 (es) * | 2005-12-23 | 2008-02-20 | Astrazeneca Ab | Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1) |
TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
WO2009054983A1 (en) * | 2007-10-24 | 2009-04-30 | Merck & Co., Inc. | Heterocycle amide t-type calcium channel antagonists |
KR101252334B1 (ko) | 2008-04-18 | 2013-04-08 | 주식회사 대웅제약 | 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
KR20130087499A (ko) | 2010-06-15 | 2013-08-06 | 메르크 파텐트 게엠베하 | 금속 착물 |
KR101293384B1 (ko) | 2010-10-13 | 2013-08-05 | 주식회사 대웅제약 | 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
AU2015329955A1 (en) * | 2014-10-08 | 2017-05-11 | Thomas Helledays Stiftelse For Medicinsk Forskning | Heterocyclic compounds as DCTPP1 modulators |
JO3719B1 (ar) | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
JP2018052817A (ja) * | 2015-01-21 | 2018-04-05 | 大日本住友製薬株式会社 | 新規ベンズイミダゾール誘導体およびその医薬用途 |
US11186564B2 (en) | 2016-08-04 | 2021-11-30 | Sunovion Pharmaceuticals Inc. | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders |
EP3908574A4 (en) * | 2019-01-08 | 2022-10-26 | Neomed Institute | CRYSTALLINE FORMS OF (S)-2-(7-CYANO-1H-BENZIMIDAZOLE-1-YL)-N-{1-[4-(1-CYANO-1-METHYLETHYL)PHENYL]ETHYL}ACETAMIDE |
CA3218090A1 (en) | 2021-05-10 | 2022-11-17 | Magnus HALLDIN | New formulations and uses |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1186504A (en) | 1966-10-15 | 1970-04-02 | Fisons Pest Control Ltd | Substituted Heterocyclic Compounds |
IT1036004B (it) * | 1968-05-21 | 1979-10-30 | Abc Ist Biolog Chem Spa | Acidt 3 indolil adetoidrossamici |
BE793718A (fr) * | 1972-01-07 | 1973-07-05 | Merck & Co Inc | Aminobenzimidazoles |
DE3347290A1 (de) * | 1983-12-28 | 1985-07-11 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel |
US4738981A (en) * | 1984-11-13 | 1988-04-19 | Warner-Lambert | Substituted trans-1,2-diaminocyclohexyl amide compounds |
JPH06759B2 (ja) | 1989-09-22 | 1994-01-05 | ファイザー製薬株式会社 | 新規なベンゾイミダゾール化合物 |
DE4309969A1 (de) | 1993-03-26 | 1994-09-29 | Bayer Ag | Substituierte heteroanellierte Imidazole |
US5403851A (en) | 1994-04-05 | 1995-04-04 | Interneuron Pharmaceuticals, Inc. | Substituted tryptamines, phenalkylamines and related compounds |
NZ324834A (en) | 1995-12-28 | 2001-11-30 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives and their use in reducing blood sugar or as inhibitors of PDE5 activity |
GB9713484D0 (en) | 1997-06-27 | 1997-09-03 | Smithkline Beecham Plc | Neuroprotective vanilloid compounds |
JP2000095767A (ja) | 1998-09-28 | 2000-04-04 | Takeda Chem Ind Ltd | 性腺刺激ホルモン放出ホルモン拮抗剤 |
CZ2002422A3 (cs) | 1999-08-12 | 2002-11-13 | Pharmacia Italia S. P. A. | 3(5)-Aminopyrazolové deriváty, způsob jejich přípravy a jejich pouľití jako protinádorová činidla |
US6534651B2 (en) * | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
WO2001085722A1 (en) | 2000-05-05 | 2001-11-15 | Cor Therapeutics, Inc. | Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors |
AU2001259707A1 (en) | 2000-06-14 | 2001-12-24 | Warner Lambert Company | 6,5-fused bicyclic heterocycles |
US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
AU2001278771A1 (en) | 2000-08-22 | 2002-03-04 | Ono Pharmaceutical Co. Ltd. | Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient |
GB0031315D0 (en) * | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Indole derivatives |
ITTO20010110A1 (it) | 2001-02-08 | 2002-08-08 | Rotta Research Lab | Nuovi derivati benzamidinici dotati di attivita' anti-infiammatoria ed immunosoppressiva. |
GB0105895D0 (en) | 2001-03-09 | 2001-04-25 | Smithkline Beecham Plc | Novel compounds |
SE0101387D0 (sv) | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | Novel compounds |
GB0110901D0 (en) | 2001-05-02 | 2001-06-27 | Smithkline Beecham Plc | Novel Compounds |
IL158590A0 (en) | 2001-06-11 | 2004-05-12 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
TWI239942B (en) * | 2001-06-11 | 2005-09-21 | Dainippon Pharmaceutical Co | N-arylphenylacetamide derivative and pharmaceutical composition containing the same |
AU2002325381A1 (en) | 2001-07-31 | 2003-02-24 | Bayer Healthcare Ag | Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists |
MY138086A (en) | 2001-09-13 | 2009-04-30 | Smithkline Beecham Plc | Novel urea derivative as vanilloid receptor-1 antagonist |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
JP2005518371A (ja) | 2001-12-10 | 2005-06-23 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療に於けるこれらの使用 |
GB0130550D0 (en) | 2001-12-20 | 2002-02-06 | Smithkline Beecham Plc | Novel compounds |
EP1480954B1 (en) | 2002-02-15 | 2008-12-03 | Glaxo Group Limited | Vanilloid receptor modulators |
US20030158188A1 (en) * | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
BR0311952A (pt) | 2002-06-20 | 2005-04-19 | Biovitrum Ab | Novos compostos úteis para o tratamento de obesidade, diabetes tipo ii e distúrbios do snc |
GB0221157D0 (en) | 2002-09-12 | 2002-10-23 | Glaxo Group Ltd | Novel treatment |
AU2003270199A1 (en) | 2002-09-13 | 2004-04-30 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
JP2006505570A (ja) * | 2002-10-17 | 2006-02-16 | アムジエン・インコーポレーテツド | ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用 |
SE0301446D0 (sv) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
SE0301701D0 (sv) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
DK1664036T3 (da) * | 2003-09-03 | 2012-02-13 | Pfizer | Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning |
WO2005095327A1 (ja) * | 2004-03-31 | 2005-10-13 | Ajinomoto Co., Inc. | アニリン誘導体 |
SE0402284D0 (sv) * | 2004-09-21 | 2004-09-21 | Astrazeneca Ab | New heterocyclic amides |
AR058705A1 (es) * | 2005-12-23 | 2008-02-20 | Astrazeneca Ab | Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1) |
EP2038259A1 (en) * | 2006-06-29 | 2009-03-25 | F.Hoffmann-La Roche Ag | Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same |
TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
-
2006
- 2006-12-20 AR ARP060105673A patent/AR058705A1/es not_active Application Discontinuation
- 2006-12-20 UY UY30048A patent/UY30048A1/es unknown
- 2006-12-20 TW TW095148018A patent/TW200736227A/zh unknown
- 2006-12-21 AT AT06835882T patent/ATE538101T1/de active
- 2006-12-21 RU RU2008122404/04A patent/RU2427573C2/ru not_active IP Right Cessation
- 2006-12-21 UA UAA200807385A patent/UA96277C2/ru unknown
- 2006-12-21 NZ NZ569923A patent/NZ569923A/en unknown
- 2006-12-21 US US11/614,346 patent/US7618993B2/en active Active
- 2006-12-21 EP EP06835882A patent/EP1966156B1/en active Active
- 2006-12-21 CA CA002634804A patent/CA2634804A1/en not_active Abandoned
- 2006-12-21 BR BRPI0620410-4A patent/BRPI0620410A2/pt not_active IP Right Cessation
- 2006-12-21 JP JP2008547169A patent/JP2009521431A/ja active Pending
- 2006-12-21 WO PCT/SE2006/001467 patent/WO2007073303A2/en active Application Filing
- 2006-12-21 AU AU2006327320A patent/AU2006327320B2/en not_active Ceased
- 2006-12-21 KR KR1020087017908A patent/KR20080080212A/ko active IP Right Grant
- 2006-12-21 CN CN2006800533688A patent/CN101389610B/zh not_active Expired - Fee Related
- 2006-12-21 ES ES06835882T patent/ES2377661T3/es active Active
-
2008
- 2008-05-27 IL IL191753A patent/IL191753A0/en unknown
- 2008-06-12 ZA ZA200805162A patent/ZA200805162B/xx unknown
- 2008-06-27 EC EC2008008584A patent/ECSP088584A/es unknown
- 2008-07-22 NO NO20083246A patent/NO20083246L/no not_active Application Discontinuation
-
2009
- 2009-02-20 HK HK09101612.7A patent/HK1121755A1/xx not_active IP Right Cessation
- 2009-10-14 US US12/578,730 patent/US8168668B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
NZ569923A (en) | 2011-04-29 |
RU2427573C2 (ru) | 2011-08-27 |
EP1966156A2 (en) | 2008-09-10 |
HK1121755A1 (en) | 2009-04-30 |
CN101389610A (zh) | 2009-03-18 |
KR20080080212A (ko) | 2008-09-02 |
WO2007073303A3 (en) | 2007-08-30 |
EP1966156B1 (en) | 2011-12-21 |
ECSP088584A (es) | 2008-07-30 |
JP2009521431A (ja) | 2009-06-04 |
NO20083246L (no) | 2008-09-11 |
US20100286202A1 (en) | 2010-11-11 |
ZA200805162B (en) | 2009-11-25 |
US7618993B2 (en) | 2009-11-17 |
UY30048A1 (es) | 2007-07-31 |
WO2007073303A2 (en) | 2007-06-28 |
CN101389610B (zh) | 2011-12-07 |
AU2006327320A1 (en) | 2007-06-28 |
CA2634804A1 (en) | 2007-06-28 |
ES2377661T3 (es) | 2012-03-29 |
ATE538101T1 (de) | 2012-01-15 |
TW200736227A (en) | 2007-10-01 |
AU2006327320B2 (en) | 2009-12-10 |
BRPI0620410A2 (pt) | 2011-11-08 |
US20080171770A1 (en) | 2008-07-17 |
RU2008122404A (ru) | 2010-01-27 |
US8168668B2 (en) | 2012-05-01 |
UA96277C2 (en) | 2011-10-25 |
IL191753A0 (en) | 2008-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR058705A1 (es) | Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1) | |
ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
AR077818A1 (es) | Composiciones pesticidas | |
AR053994A1 (es) | Sulfonilpirrolidinas sustituidas procedimiento para su preparacion y su uso como medicamentos | |
AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
NO20084350L (no) | Heterocykliske amider til anvendelse som farmasoytika | |
ES2543607T3 (es) | Ciertas amidas sustituidas, método de obtención, y método de su uso | |
RS53348B (en) | PROCEDURE FOR THE PREPARATION OF 3-SUBSTITUTED 2-AMINO-5-HALOBENZAMIDES | |
RS54848B1 (sr) | Nova pesticidna jedinjenja na bazi pirazola | |
UY30824A1 (es) | Nuevos derivados de idazolil éster o amida, composiciones farmacéuticas conteniéndolas, procesos de preparacion y aplicaciones. | |
CL2008002998A1 (es) | Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion. | |
CO6241076A2 (es) | Compuestos de benzamida y aplicaciones de los mismos | |
AR058403A1 (es) | PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF. | |
EA200600527A1 (ru) | Активирующее ppar соединение и содержащая его фармацевтическая композиция | |
EA200870362A1 (ru) | Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида | |
AR060813A1 (es) | Moduladores de mglur5 iii | |
AR079748A1 (es) | Arilpirrolidinas plaguicidas | |
AR063906A1 (es) | Compuestos quimicos derivados del indazol, una composicion farmaceutica y procesos de prpeparacion de los compuestos | |
PE20070829A1 (es) | Inhibidores cetp heterociclicos | |
HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
UY29070A1 (es) | Enantiómeros de heterocíclicos fusionados y sus usos | |
PE20091930A1 (es) | Compuestos de pirazol, procesos para su produccion y herbicidas que los contienen | |
RS53658B1 (en) | 5-FLUORO-2-OXOPYRIMIDINE-1 (2H) -CARBOXYLATE DERIVATIVES AS FUNGICIDES | |
NO20054225L (no) | Benzamid-derivater som oksytocin-agonister og vasopressin-antagonister | |
ES2578628T3 (es) | Compuestos de L-dihidro-2-oxoquinolina como ligandos del receptor de 5-HT4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |